Well Referenced

Tag: lipid-lowering therapy

Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk

This comprehensive review highlights lipoprotein(a) [Lp(a)] as a genetically determined, independent risk factor for various cardiovascular diseases, including coronary artery disease, aortic valve stenosis, ischemic stroke, heart failure, and peripheral arterial disease. Elevated Lp(a) levels (≥50 mg/dL or ≥100 nmol/L) are prevalent in approximately 20% of the population and contribute

Read More »
June 26, 2025 No Comments

Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

This 2024 systematic review and meta-analysis evaluated the efficacy of cholesteryl ester transfer protein inhibitors (CETPis) in reducing cardiovascular events. Analyzing nine randomized controlled trials conducted between 2003 and 2023, the study found that CETPis significantly reduced cardiovascular disease (CVD)-related mortality (RR = 0.89; 95% CI: 0.81–0.98; p = 0.02)

Read More »
June 26, 2025 No Comments

Primary Prevention with Lipid Lowering Drugs and Long-Term Risk of Vascular Events in Older People: Population-Based Cohort Study

This population-based cohort study from France included 7,484 community-dwelling adults aged 65 years and older without a history of vascular events. It aimed to assess whether lipid-lowering drugs (mainly statins and fibrates) reduce the long-term risk of stroke and coronary heart disease (CHD) in a primary prevention setting. Over a

Read More »
June 26, 2025 No Comments

Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes

This review article discusses the clinical significance of lipoprotein(a) [Lp(a)] as an independent risk factor for cardiovascular diseases, including coronary artery disease and calcific aortic valve disease. It highlights that Lp(a) levels are genetically determined and remain constant throughout life. The article emphasizes the importance of measuring Lp(a) levels for

Read More »
June 26, 2025 No Comments

Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial

This randomized controlled trial evaluated the effects of atorvastatin (20 mg daily), vitamin C (1 g daily), and vitamin E (1,000 U daily) on coronary artery calcification and cardiovascular events in 1,005 asymptomatic adults aged 50 to 70 with elevated coronary calcium scores. Over a mean follow-up of 4.3 years,

Read More »
June 26, 2025 No Comments

Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial

This randomized controlled trial evaluated the effects of intensive versus standard atorvastatin therapy on the progression of coronary artery calcification (CAC) in patients with cardiovascular risk factors but no significant coronary stenosis. The study found that intensive atorvastatin therapy slowed the progression of CAC by 30% compared to standard therapy

Read More »
June 26, 2025 No Comments

Evacetrapib Fails to Reduce Major Adverse Cardiovascular Events

The study evaluated the efficacy of evacetrapib, a CETP inhibitor, in reducing major adverse cardiovascular events (MACE) despite its ability to significantly raise HDL cholesterol by 130% and lower LDL cholesterol by 37%. Conducted on over 12,000 high-risk cardiovascular patients, the trial was halted early due to a lack of

Read More »
June 26, 2025 No Comments